Adult Malignant Glioma Therapeutics Market Size, Share and Industry Analysis Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User, and Regional Forecast 2019-2026

Methodology:

Fortune Business Insights follows a robust research methodology that involves data triangulation based on top-down, bottom-up approaches, and validation of the estimated market numbers through primary research. The information used to estimate the market size and forecast for various segments at the global, regional, and country level is derived from the most credible published sources and through interviews with the right stakeholders.

Growth rate or CAGR exhibited by a market for a certain forecast period is calculated on the basis of various factors and their level of impact on the market. These factors include market drivers, restraints, industry challenges, market and technological developments, market trends, etc.

SECONDARY DATA SOURCES THAT WE REFER TO:

• Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market
• Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.
• Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics
• Industry journals and paid databases

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

• Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
• Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
• Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
• Number of procedures and average price of procedures
• Replacement rate and pricing of capital equipment
• Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
• Market & technological trends, new product developments, product pipeline.

INTERVIEWS ARE CONDUCTED WITH:

• Key stakeholders such as purchasing managers, nurses, pharmacists, surgeons, physicians, etc. in end-use facilities such as hospitals, clinics, ambulatory surgery centers, pharmacies, research institutes, etc.
• Key opinion leaders in related associations
• Key stakeholders such as C-level executives, marketing managers, product managers, sales managers, etc. in major companies (suppliers and distributors) operating in the market

INTERVIEWS ARE CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

• Insights from supply side respondents in relation to the market size, growth rate, market distribution, market dynamics, and market share analysis
• Validation of the market size, growth rate, and market distribution estimated on the basis of market models
• Insights from end user respondents to feed into models such as patient/procedure numbers, distribution of patients by treatment type, average pricing, average spending on devices, replacement rate of capital equipment, etc.